Skip to content

Compare the efficiency of Laser treatment vs Chemical peels treatment in patients with mealsma(facial hyperpigmentation)

Comparison of Modified Melasma Area and Severity Index (mMASI) scores between low fluence Q-switched Nd:YAG laser vs 35 % glycolic acid peels for melasma: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/03/017943
Enrollment
90
Registered
2019-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: 35 % Glycolic acid peels: Maximum 4 sessions of 35 % glycolic acid peels at 4 weekly intervals for a period of 12 weeks Control Intervention1: low fluence Q-switched Nd:YAG laser: Low f

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.All patients of melasma of age more than 18 years attending the dermatology OPD, JIPMER 2.Patients of melasma who has received any topical treatment (after washout period of 2 weeks)

Exclusion criteria

Exclusion criteria: 1.Other causes of facial melanosis (such as lichen planus pigmentosus, erythema dyschronicum perstans, pigmented contact dermatitis, post-inflammatory hyperpigmentation) 2.Pregnant and lactating mothers 3.Patients currently using oral contraceptives 4,History of endocrinopathies 5.Patients on hormone replacement therapies 6.Patients with hypersensitivity to chemical peels

Design outcomes

Primary

MeasureTime frame
Post treatment mMASI scores between Laser group vs Peels groupTimepoint: Post treatment mMASI scores assessed at 0,1 month,2 months and 3 months after starting treatment

Secondary

MeasureTime frame
Side effect profile between Laser group and Peels groupTimepoint: 0,1month,2months,3months

Countries

India

Contacts

Public ContactDr Rashmi kumari

JIPMER

rashmi.sreerag@gmail.com9489692199

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026